共 141 条
[1]
Costa L(2008)Impact of skeletal complications on patients’ quality of life, mobility, and functional independence Support Care Cancer 16 879-889
[2]
Badia X(2010)Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study J Clin Oncol 28 5132-5139
[3]
Chow E(2014)Bone health in cancer patients: ESMO Clinical Practice Guidelines Ann Oncol 25 iii124-iii137
[4]
Lipton A(2013)Management of bone metastases secondary to breast cancer: a comprehensive survey of practice patterns in five European countries Eur J Cancer 49 abstr 1880-1673
[5]
Wardley A(2014)Use of intravenous bisphosphonates in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems Support Care Cancer 22 1363-453
[6]
Stopeck AT(2015)Clinical practice guidelines for breast cancer: current limitations Breast J 21 450-1653
[7]
Lipton A(2010)Prevalence of renal insufficiency in breast cancer patients and related pharmacological issues Breast Cancer Res Treat 124 745-1635
[8]
Body JJ(2011)Effects of denosumab on fracture and bone mineral density by level of kidney function J Bone Miner Res 26 1829-907
[9]
Steger GG(2006)Management of the adverse effects associated with intravenous bisphosphonates Ann Oncol 17 897-1821
[10]
Tonkin K(2015)Hypocalcaemia in patients with metastatic bone disease treated with denosumab Eur J Cancer 51 1812-455